louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05206123: Sexual Needs of Adolescents Living With HIV Since Childhood
Official title: Sexual Health Needs of Adolescents Living With HIV Since Childhood : a Qualitative Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hiv
Perinatal HIV Infection
Keywords: HIV
sexual Health
adolescent
sexual needs
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2022-01-25
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young adults with a perinatally acquired HIV infection

Brief summary: To improve the knowdelge about the sexual health needs of perinatally HIV-infected adolescents living in France.

Detailed description: 20 individual semi-structured interviews will be conducted with 20 young adults living with HIV sinc childhood and living in France. The aim of this study is to identify their sexual needs through exploring their personal experience of sexuality during their adolescence. The investigator intend to explore communication about the disease and sexuality within their families ; communication about sexual health with health care professionnals ; whether sexuality has arrose difficulties related to their chronic condition such as rejection or sadness ; whether there are differences in sexual needs regarding gender. A thematic analysis will be conducted by three researchers.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 25 yo
* HIV-1 or HIV-2 diagnosis before the age of 13
* non opposition to participate to the study
* be affiliated to a social security scheme (except Aide Médicale de l'Etat (AME))

Exclusion Criteria:

* having contracted HIV infection through sexual contact
* persons under guardianship or custodianship, or deprived of their liberty by a judicial or administrative decision
* associated illnesses or disabilities that makes participation impossible

Primary outcomes:
measure: Qualitative analysis
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Maison de Solenn
Study officials:
References:
Clinical trial NCT06695923: Different Ultrafiltration Rates and Intradialytic Hypotension.
Official title: Association of Ultrafiltration Rates and Intradialytic Hypotension in Sohag University Hospitals.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hemodialysis
Intradialytic Hypotension
Keywords: Ultrafiltration rates
Intradialytic hypotension
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-11-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hemodialysis patients more than 18 year old on maintenance hemodialysis receiving 3 sessions weekly.

Brief summary: Finding relationship between different ultrafiltration rates and intradialytic hypotension in attempt to find the optimal cut off points.

Detailed description: This observational study will be carried upon hemodialysis patients with different ultrafiltration rates at each session to study the association between ultrafiltration rates and intradialytic hypotension.

Thus identifying the optimal cut off of ultrafiltration rate points for each patient

Eligibility criteria: Inclusion Criteria:

All patients aged 18 Year or older on maintenance haemodialysis for at least 3 consecutive months receiving 3 sessions weekly.

-

Exclusion Criteria:

Patients aged \< 18 years old.

Patients on recent haemodialysis \< 3 months.

Pregnant women.

Patients with malignancy, severe infections or sepsis.

Patients with major bleeding.

Patients who cannot go upper limb monitoring of blood pressure.

Patients with severe heart failure (NYHA) class 3 or more.

Patients with severe anemia, Hemoglobin less than 6 g/dl.

Primary outcomes:
measure: Prevent intradialytic hypotension
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospitals,Faculty of medicine
Study officials:
References:
Clinical trial NCT00514423: How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs
Official title: How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Schizoaffective Disorder
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2007-08-10
Enrollment: 896
Sex: ALL
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Participation in one of the three interventions psychoeducation by professionals, psychoeducation by peer-moderators, or video-education can reduce the rehospitalisation rate of patients with schizophrenia compared to a control group.


Eligibility criteria: Inclusion Criteria:

* Schizophrenia or schizoaffective disorder (ICD-10)
* Age 18 to 67 years
* Hospitalised or treated in day care clinic

Exclusion Criteria:

* More than 12 months of hospitalisation within the last two years
* Substance-dependency (principal diagnosis)
* Mental retardation ICD-10 Chapter F70-79
* Fluency of German language not given

Primary outcomes:
measure: Rehospitalisation rate
Secondary outcomes:
measure: Rehospitalisation days
measure: Resulting costs per patient
measure: Compliance
measure: Knowledge of illness
measure: Attitude towards illness
measure: Quality of life
measure: Satisfaction with treatment
measure: Duration of consultation time
measure: Dealing with mental illness
Other outcomes:
Locations:
city: München
country: Germany
facility: Klinik und Poliklinik für Psychiatrie und Psychotherapie am Klinikum rechts der Isar der Technischen Universität München
Study officials:
affiliation: Technical University of Munich
name: Werner Kissling, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06386523: Standardization of a New Psychophysical Olfactory Test, TODA2
Official title: Standardization of a New Psychophysical Olfactory Test, TODA2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients Without an Olfactory Disorder
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2024-04-26
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Recruitment of patients consulting the IUFC for another pathology unrelated to an olfactory disorder:

Interview and clinical examination and Passing the 2 olfactory tests for 30 voluntary's patients, a second consultation of 15 minutes including the time of the test within 7 days after the 1st

Detailed description: Recruitment of patients consulting the IUFC for another pathology unrelated to an olfactory disorder (otosclerosis, pre- surgery, tonsillectomy, cosmetic surgery)

Data collection methods: 2 parts (duration approximately 1.5 hours) and for 30 volunteer patients, a second consultation of 15 minutes including the time of the test within 7 days after the 1st:

1. Interview and clinical examination
2. Passage of olfactory tests: TODA2 and Sniffin Stick Test in unirhinal
3. On a voluntary basis, and within a limit of 30 patients, those who agree to come back a second time will be able to benefit from a second pass of the TODA2 on Day 7.

Eligibility criteria: Inclusion Criteria:

* Subjects \> 18 years old
* No olfactory complaints; subjective estimation of "normal" olfaction
* Affiliated to the Social Security system
* Signing of informed consent

Exclusion Criteria:

* Parosmia/phantosmia, hyposmia/anosmia, pre-existing subjective dysgeusia/ageusia
* ATCD of sinus or cranial neoplasia
* ATCD of sinus or cranial radiotherapy
* Neurological or neurodegenerative disease
* ATCD of persistent post-viral hyposmia or anosmia (including COVID) (more than 3 months)

Primary outcomes:
measure: Passage of olfactory tests:
timeFrame: Day 0
measure: Passage of olfactory tests:
timeFrame: Day 0
measure: Passage of olfactory tests:
timeFrame: Day 7
Secondary outcomes:
measure: Identify confounding factors, i.e. factors that can influence the results of the olfactory test
timeFrame: Day 0
measure: Identify confounding factors, i.e. factors that can influence the results of the olfactory test
timeFrame: Day 0
Other outcomes:
Locations:
city: Cannes
country: France
facility: CH de Cannes
city: Nice
country: France
facility: CHU de Nice
Study officials:
affiliation: Centre Hospitalier Universitaire de Nice
name: Clair VANDERSTEEN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06464523: HPV Education, Early Diagnosis and Knowledge
Official title: The Effect of HPV Training on Early Diagnosis Screening and Knowledge Levels of Female Teachers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Female Teachers
Lead sponsor: Mehmet Akif Ersoy University
Sponsor class: OTHER
First posted: 2024-06-18
Enrollment: 156
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study was to determine the effect of health education given to female teachers on HPV knowledge and screening test. The population of the study consisted of all female teachers belonging to the Bucak Directorate of National Education between September 2021 and March 2022. The sample of the study consisted of 144 healthy female teachers who were registered in the institutions affiliated to the District Directorate of National Education between the specified dates, met the inclusion criteria and volunteered to participate in the study. In this study area, with the assumption that the rate of cervical cancer screening test of 70% of the women in the Healthy Life Centre after the trainings would be considered significant, the effect size d=0.18 was calculated to include at least 98 women in 3 groups at 95% power and 0.05 error level. The calculation was performed with the 'G Power 3.1.9.2' package programme. In this context, the total sample of the study was determined as 156 participants, 52 in each group.


Eligibility criteria: Inclusion Criteria:

* to volunteer to participate in the study,
* To be between the ages of 30-65,
* being a woman teacher,
* being married
* to be able to make video calls.

Exclusion Criteria:

* being pregnant or in the postnatal period,
* a history of cervical cancer,
* to have hysterectomy operation.

Primary outcomes:
measure: Human Papilloma Virus (HPV) Knowledge Scale:
timeFrame: 5-10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Burdur
country: Turkey
facility: Burdur Mehmet Akif Ersoy University
state: Bucak
Study officials:
References:
citation: Bayik Temel A, Daghan S, Kaymakci S, Ozturk Donmez R, Arabaci Z. Effect of structured training programme on the knowledge and behaviors of breast and cervical cancer screening among the female teachers in Turkey. BMC Womens Health. 2017 Dec 7;17(1):123. doi: 10.1186/s12905-017-0478-8.
citation: Kocaoz S, Ozcelik H, Talas MS, Akkaya F, Ozkul F, Kurtulus A, Unlu F. The Effect of Education on the Early Diagnosis of Breast and Cervix Cancer on the Women's Attitudes and Behaviors Regarding Participating in Screening Programs. J Cancer Educ. 2018 Aug;33(4):821-832. doi: 10.1007/s13187-017-1193-8.
citation: Keten HS, Ucer H, Dalgaci AF, Isik O, Ercan O, Guvenc N. Knowledge, Attitude, and Behavior of Teachers Regarding HPV (Human Papillomavirus) and Vaccination. J Cancer Educ. 2021 Jun;36(3):584-590. doi: 10.1007/s13187-019-01668-2.
Clinical trial NCT00406523: A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Heart Disease
Lead sponsor: Shenyang Northern Hospital
Sponsor class: OTHER
First posted: 2006-12-04
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) in inhibiting of restenosis in percutaneous coronary intervention (PCI) real world and to observe the safety and efficacy of 4 months'clopidogrel treatment after implantation of JANUS stent.

Patients were enrolled and randomized to be treated by JANUS or SRNCRO (bare metal stent with the same platform as JANUS). All enrolled patients received daily clopidogrel for 4 months and aspirin for life long for post-PCI period(In AMI group, patients received daily clopidogrel 150mg for 2 weeks at first). The primary endpoints included death of heart, myocardial infarction, revascularization of the target lesson, sub-acute and late stent thrombosis one year after PCI, The secondary endpoints included MACE at 30 days, 6 months and restenosis by follow-up angiogram at 6 to 12 months.


Eligibility criteria: Inclusion Criteria:

* Patients who were eligible for coronary stenting
* All patients enrolled were implanted only one kind of stent
* Stent number ≤ 8 per patient and ≤3 per vessel (stents overlapping part for 3～5mm and being fully post-dilated; Total stent length ≤ 85mm in same vessel)
* Willing and able to sign informed consent.

Exclusion Criteria:

* Patients with multi-vessel disease could not be implanted the same kind of stent
* In-stent restenosis target lesion
* Patients not eligible for DES implantation (e.g. intolerance to anti-platelet therapy or undergoing heart or non-heart surgery recently

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Shenyang Northern Hospital
name: Yaling Han, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03351023: Healthful Diets and Risk of Hearing Loss
Official title: Healthful Dietary Patterns and Risk of Hearing Loss in Women
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hearing Loss
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2017-11-22
Enrollment: 70966
Sex: FEMALE
Minimum age (years): 27
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The Conservation of Hearing Study (CHEARS) examines risk factors for hearing loss among participants in the Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time. After exclusions, a total of 70,966 women were included in the analyses.

Brief summary: To prospectively examine the relations between adherence scores for three healthful dietary patterns, the Alternate Mediterranean diet (AMED), the Dietary Approaches to Stop Hypertension (DASH), and the Alternative Healthy Eating Index (AHEI-2010), and risk of hearing loss in the Nurses' Health Study II.


Eligibility criteria: Inclusion Criteria:

* The investigators limited the study to women who provided information on their hearing on the 2009 or 2013 questionnaire.

Exclusion Criteria:

* The investigators excluded those who did not provide responses to the hearing questions on either questionnaire, reported a hearing problem that began before baseline for the current analysis (1991) or did not report date of onset, or reported cancer other than non-melanoma skin cancer. The investigators also excluded women who did not complete the baseline diet questionnaire and who had missing diet information for each subsequent time period.

Primary outcomes:
measure: Hearing loss
timeFrame: 1991-2013
Secondary outcomes:
measure: hearing loss in HSSQ
timeFrame: 1991-2013
Other outcomes:
Locations:
Study officials:
affiliation: Brigham and Women's Hospital/Harvard Medical School
name: Gary Curhan, MD, ScD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00825838: Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase
Official title: A Randomized Double-Blind Placebo-Controlled Clinical Trial of a Purified Chili Pepper Extract (CH-19 Sweet Extract) to Evaluate Its Safety and Efficacy for Weight and Fat Loss and Metabolism Change in Overweight or Obese Healthy Male and Female Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Overweight
Obesity
Keywords: Body weight
Body composition
Resting metabolic rate and fat oxidation in men
class I obese
Lead sponsor: Ajinomoto USA, INC.
Sponsor class: INDUSTRY
First posted: 2009-01-21
Enrollment: 80
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test the safety and effectiveness of a purified extract of CH-19 Sweet, containing capsinoids.


Eligibility criteria: Inclusion Criteria:

* Is overweight or obese but otherwise generally healthy who interested in losing weight
* BMI of 25 to 35 kg/m2
* Waist/hip ratio of 0.9 or more for male and 0.85 for female.

Exclusion Criteria:

* Type 1 or 2 diabetes mellitus
* cardiovascular disease (other than mild, controlled hypertension or dislidemia)
* On a weight-loss program within six months

Primary outcomes:
measure: body weight and body composition
timeFrame: 12 weeks
Secondary outcomes:
measure: resting metabolic rate and substrate oxidation
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: University of Maryland, Baltimore
name: Soren Snitker, M.D., Ph.D.
role: STUDY_CHAIR
affiliation: Ajinomoto USA, INC.
name: Yoshiyuki Fujishima, D. Phil.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03371238: Effect of Floorball on Healthy Subjects
Official title: The Effect of Floorball on Health and Performance Parameters in Healthy Seniors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Aging Problems
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2017-12-13
Enrollment: 500
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: To investigate the effect of floorball on health and performance in healthy subjects over 65 years.


Eligibility criteria: Inclusion Criteria:

* Healthy
* age 65-85
* physical activity \<2 hours pr. week.

Exclusion Criteria:

* age \<18 years
* Injuries that prevent the subject from playing floorball
* Alcohol \>14 units pr. week.
* Pregnancy
* Other serious conditions

Primary outcomes:
measure: Echocardiogram
timeFrame: Changes from baseline measured after 12 weeks and 39 weeks
measure: Bodycomposition
timeFrame: Changes from baseline measured after 12 weeks and 39 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: August Krogh Building
Study officials:
References:
Clinical trial NCT01327638: Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
Official title: Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spondylarthropathies; Spondylitis, Ankylosing
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2011-04-01
Enrollment: 21108
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Out-patients in Sweden with SpA/AS who took etoricoxib, other COX-2 inhibitors, or nsNSAIDs from 2001-2010.

Brief summary: The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.

Detailed description: The specific project objectives are to:

1) Describe the characteristics of Swedish patients with inflammatory SpA/AS ; 2) Describe the use of etoricoxib and other cyclooxygenase-2 (COX-2 inhibitors)/non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in Swedish patients with SpA/AS; and 3) Estimate and compare the rates of clinical outcomes of special interest (gastrointestinal, renovascular, cardiovascular and cerebrovascular) with use of etoricoxib and other COX-2 inhibitors/nsNSAIDs in Swedish patients with SpA/AS. Comparisons of clinical outcomes among the drugs of interest will be made by descriptive comparison of the point estimates for the incidence rates and their associated 95% confidence intervals (CIs), using both clinical and epidemiological judgment and in light of the limitations of this observational study. No formal statistical significance testing will be performed for purposes of such comparisons.

Eligibility criteria: Inclusion Criteria:

* Participant attended an out-patient clinic 2001-2010.
* Participant is registered with an International Classification of diseases (ICD, Version 10)-code corresponding to SpA/AS and AS.

Exclusion Criteria:

Not applicable.

Primary outcomes:
measure: Number of patients with Characteristics of inflammatory SPA/AS
timeFrame: Over a 12 year period (2001-2013)
measure: Number of patients who used etoricoxib
timeFrame: Up to 7 1/2 years (Q3 2005 - 2013)
measure: Number of patients who used other COX-2 inhibitors
timeFrame: Up to 7 1/2 years (Q3 2005 - 2013)
measure: Number of patients who used nsNSAIDs
timeFrame: Up to 7 1/2 years (Q3 2005 - 2013)
measure: Number of clinical outcomes of special interest
timeFrame: Up to 7 1/2 years (Q3 2005 - 2013)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: